ArticleHealth science reports2025
Development and Validation of a Nomogram for Predicting Intravenous Amiodarone-Induced Phlebitis: A Prospective Cohort Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Validation of a Nomogram for Predicting Intravenous Amiodarone-Induced Phlebitis: A Prospective Cohort Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous amiodarone is primarily used to treat hemodynamically unstable atrial or ventricular arrhythmias and prevent atrial fibrillation after cardiac surgery. However, when administered via peripheral intravenous infusion, the incidence of phlebitis is relatively high. This increase in complication rate not only increases patient discomfort and prolongs hospitalization but may also adversely affect treatment efficacy and quality of life. Therefore, early identification of high-risk patients and timely intervention are crucial for reducing the occurrence of phlebitis, enhancing treatment safety, and improving patient prognosis. Aim: This study aimed to develop and validate a nomogram to predict the risk of phlebitis associated with peripheral intravenous injection of amiodarone. Design: This study is a prospective cohort study. Methods: The research was carried out at Guigang People's Hospital in China. A total of 393 cases who underwent intravenous infusion of amiodarone through the peripheral vein between January 2022 and December 2023 constituted the study cohort. The cohort was randomly divided using computer-generated randomization numbers, with stratification maintained for key clinical characteristics (including age, infusion duration, and concentration). A 70:30 ratio allocation was applied to create a training set ( Results: Age, infusion time, infusion concentration, and whether to perform 2 h of alternating indwelling needle were factors influencing the occurrence of phlebitis associated with peripheral intravenous use of amiodarone. A nomogram model of the risk of developing phlebitis with peripheral intravenous injection of amiodarone was successfully constructed. Bootstrap results showed that the calibration curves fitted well with the ideal curves. The areas under the receiver operating characteristic (ROC) curve for the training and validation sets were 0.812 (95% CI: 0.757-0.867) and 0.798 (95% CI: 0.712-0.883), respectively. The results of Hosmer-Lemeshow goodness-of-fit test revealed Conclusions: The model showed a good predictive effect, and it can be effectively used as a tool for clinically assessing the risk of phlebitis following peripheral intravenous injection of amiodarone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.